

AroCell Q2 - An unrecognized fully financed growth case

Redeye emphasises that AroCell continues to go unnoticed by the stock market, with stable sales development, ongoing geographical expansion, and good cost control. Essentially, the Q2 financials were in line with our estimates, and we make only minor changes to our forecasts.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[AroCell Q2 - An unrecognized fully financed growth case](#)